Gene · 2176
Papers2,586
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,041 to 1,060 of 2,586
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Characteristics of cancer susceptibility genes mutations in 282 patients with gastric adenocarcinoma. | Chin J Cancer Res | 2020 | 32963463 | PubTator, text mining | PubMed |
| Canonical and Noncanonical Roles of Fanconi Anemia Proteins: Implications in Cancer Predisposition. | Cancers (Basel) | 2020 | 32962238 | PubTator, text mining | PubMed |
| Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine. | BMC Med Genomics | 2020 | 32957974 | PubTator, text mining | PubMed |
| Perioperative chemotherapy in the management of high risk upper tract urothelial cancers. | Transl Androl Urol | 2020 | 32944552 | PubTator, text mining | PubMed |
| Deep learning enables the atomic structure determination of the Fanconi Anemia core complex from cryoEM. | IUCrJ | 2020 | 32939280 | PubTator, text mining | PubMed |
| IER5, a DNA damage response gene, is required for Notch-mediated induction of squamous cell differentiation. | Elife | 2020 | 32936072 | PubTator, text mining | PubMed |
| Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer. | JCO Precis Oncol | 2020 | 32923896 | PubTator, text mining | PubMed |
| ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment. | Front Genet | 2020 | 32922441 | PubTator, text mining | PubMed |
| Emerging biomarkers in urothelial carcinoma: Challenges and opportunities. | Cancer Treat Res Commun | 2020 | 32920502 | PubTator, text mining | PubMed |
| Factors controlling accumulation of organic carbon in a rift-lake, Oligocene Vietnam. | Sci Rep | 2020 | 32917944 | PubTator, text mining | PubMed |
| Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies. | Cell Syst | 2020 | 32916097 | PubTator, text mining | PubMed |
| MicroRNAs: Diverse Mechanisms of Action and Their Potential Applications as Cancer Epi-Therapeutics. | Biomolecules | 2020 | 32906681 | PubTator, text mining | PubMed |
| Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem Cells. | Cancers (Basel) | 2020 | 32883003 | PubTator, text mining | PubMed |
| Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center. | Cancer Rep (Hoboken) | 2020 | 32881420 | PubTator, text mining | PubMed |
| PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block? | Medicines (Basel) | 2020 | 32878011 | PubTator, text mining | PubMed |
| Differential contribution of bone marrow-derived infiltrating monocytes and resident macrophages to persistent lung inflammation in chronic air pollution exposure. | Sci Rep | 2020 | 32873817 | PubTator, text mining | PubMed |
| Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going? | Int J Mol Sci | 2020 | 32872531 | PubTator, text mining | PubMed |
| The SNM1A DNA repair nuclease. | DNA Repair (Amst) | 2020 | 32866775 | PubTator, text mining | PubMed |
| Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. | Theranostics | 2020 | 32863940 | PubTator, text mining | PubMed |
| The passage from bone marrow niche to bloodstream triggers the metabolic impairment in Fanconi Anemia mononuclear cells. | Redox Biol | 2020 | 32863220 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2176/papers?page=53